The company
Gilead Sciences, Inc.
GILD · Nasdaq
Health CareBiotechnologyJust started moving
GILD stood above a rising 150-day average in 38 of the last 52 weekly readings, including each of the last 1 week. It is 13.7% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Just started moving
- Weeks in an uptrend
- 1 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $156.4M
- Officials’ trades on record
- 200
- Institutions holding
- 2,165 (-44)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 38 of 52 weeks.
17 Apr – 16 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
200 disclosed lines: House 127, Senate 56, executive 17; 49 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 24 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 23 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 23 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 12 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 15 May 2026filed 1 Jul 2026 |
| Jared Moskowitz House: U.S. House ClerkFL23 | boughtdependent child | $1k–$15k | 6 May 2026filed 19 Jun 2026 |
| Jared Moskowitz House: U.S. House ClerkFL23 | bought | $1k–$15k | 6 May 2026filed 19 Jun 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 17 Apr 2026filed 1 Jul 2026 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months45
Buyers · sellers0 · 7
| Who | Did | Shares | Traded |
|---|---|---|---|
| Andrew D. DickinsonChief Financial Officer | sold | 3,000at $156.22 | 15 Oct 2026filed 16 Oct 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | sold | 3,000at $156.22 | 15 Oct 2026filed 16 Oct 2026 |
| Daniel Patrick O'DayChairman & CEO | sold | 12,000at $147.72 | 1 Oct 2026filed 2 Oct 2026 |
| Daniel Patrick O'DayChairman & CEO | sold | 3,000at $148.63 | 1 Oct 2026filed 2 Oct 2026 |
| Andrew D. DickinsonChief Financial Officer | sold | 3,000at $145.29 | 15 Sep 2026filed 16 Sep 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | sold | 1,600at $143.69 | 15 Sep 2026filed 16 Sep 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | sold | 800at $144.46 | 15 Sep 2026filed 16 Sep 2026 |
| Johanna MercierChief Comm & Corp Aff Officer | sold | 600at $145.29 | 15 Sep 2026filed 16 Sep 2026 |
| Daniel Patrick O'DayChairman & CEO | sold | 1,600at $147.51 | 1 Sep 2026filed 2 Sep 2026 |
| Daniel Patrick O'DayChairman & CEO | sold | 7,992at $148.36 | 1 Sep 2026filed 2 Sep 2026 |
| Daniel Patrick O'DayChairman & CEO | sold | 5,408at $149.38 | 1 Sep 2026filed 2 Sep 2026 |
| Anthony WeltersDirector | sold | 3,118at $148.31 | 26 Aug 2026filed 27 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders2,165-44 on the quarter
New · exited147 · 193
Reported value$134.1B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 121,844,108$15.4B | +2,833,135+2.4% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 81,091,734$10.2B | +436,958+0.5% |
| FMR LLCreduced · filed 13 Aug 2026 | 66,870,816$8.4B | -5,035,474−7.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 61,216,552$7.7B | +1,357,967+2.3% |
| Capital World Investorsreduced · filed 12 Aug 2026 | 40,988,975$5.2B | -294,958−0.7% |
| Invesco Ltd.added · filed 14 Aug 2026 | 39,819,151$5.0B | +24,292,815+156.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 35,316,168$4.5B | +186,703+0.5% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 30,065,642$3.8B | +339,590+1.1% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 24,004,354$3.0B | +705,059+3.0% |
| Dodge & Coxreduced · filed 13 Aug 2026 | 23,677,567$3.0B | -573,259−2.4% |
31 Mar 2023 – 30 Jun 2026
News
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54247wallst.com · 15 Oct 2026Gilead Sciences signs five-year DevOps agreement with Cognizantpharmaceutical-business-review.com · 7 Oct 2026Cognizant Extends Gilead Sciences Partnership For Five Years To Scale AI-Driven DevOpssiliconindia.com · 7 Oct 2026Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?insidermonkey.com · 29 Sep 2026Gilead Sciences Inc (GILD) Stock News & Articles247wallst.com · 15 Sep 2026Gilead Sciences leads a $2 billion dividend ex-date on September 15247wallst.com · 15 Sep 2026Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?fool.com · 5 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.